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Sweden1. Summary
Campylobacter jejuni is an important cause of human foodborne gastroenteritis;
strategies to prevent infection are hampered by a poor understanding of the
complex interactions between host and pathogen. Previous work showed that
C. jejuni could bind human histo-blood group antigens (BgAgs) in vitro and
that BgAgs could inhibit the binding of C. jejuni to human intestinal mucosa
ex vivo. Here, the major flagella subunit protein (FlaA) and the major outer
membrane protein (MOMP) were identified as BgAg-binding adhesins in
C. jejuniNCTC11168. Significantly, the MOMP was shown to be O-glycosylated
at Thr268; previously only flagellin proteins were known to be O-glycosylated in
C. jejuni. Substitution of MOMP Thr268 led to significantly reduced binding to
BgAgs. The O-glycan moiety was characterized as Gal(b1–3)-GalNAc(b1–4)-
GalNAc(b1–4)-GalNAca1-Thr268; modelling suggested that O-glycosylation
has a notable effect on the conformation of MOMP and this modulates
BgAg-binding capacity. Glycosylation of MOMP at Thr268 promoted cell-to-
cell binding, biofilm formation and adhesion to Caco-2 cells, and was required
for the optimal colonization of chickens by C. jejuni, confirming the significance
of this O-glycosylation in pathogenesis.
rsob.royalsocietypublishing.org
Open
Biol.4:130202
2
 on July 8, 2016http://rsob.royalsocietypublishing.org/Downloaded from 2. Introduction
Campylobacter jejuni is the most common causative agent of
bacterial gastroenteritis reported worldwide [1]. It is respon-
sible for a spectrum of intestinal symptoms, including watery
diarrhoea, bloody diarrhoea, vomiting, fever and abdominal
cramps. Symptoms range from mild to severe and may lead
to death in immunocompromised patients [2]. Acute-phase
disease is sometimes followed by serious long-term sequelae,
including reactive arthritis [3,4], the autoimmune neuropathies
Guillain–Barre´ syndrome (GBS) and Miller–Fisher syndrome
[5] and immunoproliferative small intestinal disease [6]. The
biochemical structures of gangliosides play a crucial role in
the pathogenesis of GBS. Infection with C. jejuni is responsible
for 35% of all types of GBS and 20–30% of GBS-linked
antibodies are directed against gangliosides [7].
Prevention and treatment of the primary and secondary
consequences of Campylobacter infection are hampered by a
poor understanding of the detailed molecular interplay
between cells of the gastrointestinal lining and the pathogen.
Following ingestion, C. jejuni infect and invade the epithelium
of the small intestine and colon. Infection is dependent on
motility mediated by polar flagella and outer membrane adhe-
sins, including PEB1a, PEB3, JlpA, MOMP, CapA and CadF
[8–13]. Thus, surface-exposed bacterial ligands play major
roles inmediatingmucosal adhesionandinvasion.Campylobacter
jejuni harbours both N- and O-linked glycosylation systems
[14,15]; both have been implicated in adhesion to, and invasion
of, epithelial cells in vitro [16] and host colonization and viru-
lence in vivo [17,18]. The only target of the O-linked
glycosylation system described to date is flagellin [19], whereas
the N-linked system has a variety of targets, including periplas-
mic and outer membrane proteins [20].
Ruiz-Palacios and co-workers [21,22] showed that
fucosylated sugar components in human breast milk could
inhibit C. jejuni binding to HEp-2 cells in vitro and to
human intestinal mucosa ex vivo, and also prevent C. jejuni
infection of mice in vivo. Subsequent solid-phase assays con-
firmed the binding of C. jejuni strains, grown under host-like
conditions, to a broad range of fucose (and galactose)-
containing glycans, with different strains exhibiting differing
binding profiles and avidities [21,23]; however, the identity
of the C. jejuni lectin(s) responsible for this binding has
not to date been determined. The common ABO histo-
blood group antigens (BgAgs) comprise a complex and
polymorphic group of fucosylated carbohydrates expressed
on the surfaces of erythrocytes, but they are also highly
expressed in the oro-gastro-intestinal (OGI) epithelium, as
well as endothelial cells, and in secretions, such as milk,
saliva and tears [24,25]. Their common denominators are
the types I and II glycan core chains which may be fucosy-
lated in the bone marrow by the H-II-(fucosyl)-transferase,
before being absorbed into the surface of erythrocytes [26]
or by the H-I-(fucosyl)-transferase in the mucosal glandular
tissues, for example that along the OGI tract. Fucosylated gly-
cans are substrates for further glycosylation reactions that
give rise to the epitopes defining the A, B and Lewis BgAgs.
The ABO (or ABH) and Lewis BgAgs are epidemiologically
associated with susceptibility to several infectious agents [26].
Among enteropathogenic bacteria, Helicobacter pylori bind the
H-I and Leb antigens [27]. TheH. pylori BabA (blood group anti-
gen-binding) and SabA (sialic acid-binding adhesin) proteins
are the best described ABO/Leb and sialyl-Lewis x (sLex)antigen-binding adhesins and predictors for the development
of overt gastric disease [28,29].
Here, we identify the C. jejuni surface proteins FlaA and
MOMP as BgAg-binding adhesins. Furthermore, we show
that flagellins are not the only O-glycosylated proteins in
C. jejuni; MOMP is also O-glycosylated, a modification
that influences the MOMP conformation and thus BgAg
interactions. MOMP O-glycosylation promoted biofilm for-
mation and auto-aggregation, and was required for optimal
adhesion to Caco-2 cells and colonization of chickens, confirm-
ing the significance of this post-translational modification in
C. jejuni pathogenesis.3. Results
3.1. Campylobacter jejuni binds a wide range of human
histo-BgAgs
To confirm that C. jejuni binds BgAgs, the core-I, core-II, H-II,
Leb, Ley and Lex BgAgs were adsorbed to the surface of
amino-linked ELISA plates and incubated with digoxigenin
(DIG)-labelled C. jejuni strain NCTC11168. The structures
of these molecules are shown in the electronic supplemen-
tary material, table S1. NCTC11168 bound to each of the
glycoconjugates tested (figure 1a). Importantly, the pre-
incubation of NCTC11168 with soluble BgAgs inhibited
binding in this assay (figure 1a). In addition, 45 clinical iso-
lates of C. jejuni (see electronic supplementary material,
table S2) also bound to many of the same BgAgs, albeit to
a varied degree (see electronic supplementary material,
table S3) confirming that BgAg binding is a widespread
phenotypic trait among C. jejuni isolates.
3.2. Campylobacter jejuni FlaA and MOMP mediate
binding to human BgAgs
A technique employing a multi-functional cross-linker, termed
as retagging [29], was used for the identification of C. jejuni
BgAg-binding adhesins. NCTC11168 cells were incubated
with BgAg conjugated to a light-activated cross-linker. Follow-
ing photo-activation and subsequent exposure to reducing
conditions to allow transfer of the reactive biotin moiety to
molecules in close proximity to the BgAgs, bacteria were
lysed and the biotin-tagged C. jejuni proteins purified with
streptavidin-coated magnetic beads, as previously described
[29]. Extracted biotin-tagged proteins were separated by
SDS-PAGE and identified using MALDI-TOF. Two proteins
were identified: the 45 kDa major outer membrane protein
(MOMP) and the 59 kDa flagellin FlaA (figure 1b). FlaA is
the major flagellin and is required for the expression of func-
tional flagella. To confirm that this molecule contributed to
the observed BgAg-binding activity, flaA was deleted in
NCTC11168 and the mutant tested for its ability to bind to
BgAgs in ELISA experiments. Deletion of flaA led to signifi-
cantly reduced binding of the NCTC11168 mutant to all
examined BgAgs (figure 2a). MOMP, encoded by porA, is an
essential multi-functional porin [30]. As it was not possible
to delete porA, we purified the MOMP under non-denaturing
conditions from strain NCTC11168. The purified protein sig-
nificantly inhibited binding of NCTC11168 to the H-II
glycoconjugate (figure 2b).
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Figure 1. Binding of C. jejuni to BgAgs and identification of C. jejuni BgAg-binding adhesins. (a) Binding of digoxigenin (DIG)-labelled C. jejuni NCTC11168 to ELISA
wells coated with BgAgs. Specific binding was calculated by subtracting the bovine serum albumin (BSA; negative control) values from the BSA–BgAg absorbance.
Binding was significantly inhibited ( p , 0.05) by the pre-incubation of bacteria with soluble glycoconjugates H-II, Leb or Ley prior to adding to the ELISA plate. NT,
non-treated. Error bars: mean of triplicate values+ s.e.m. from three independent experiments. (b) Identification of BgAg-binding proteins from C. jejuni
NCTC11168 using re-tagging (baits used: H-II; H-I and Leb). Two proteins were identified at sizes of 45 and 59 kDa, corresponding to MOMP and FlaA, respectively.
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BothO- andN-glycosylation systems have been described in
C. jejuni. FlaA is a known glycoprotein that is post-transla-
tionally modified with O-linked glycans that can constitute
up to 10% of the molecule’s mass [31]. Furthermore, an
increasing number of periplasmic and outer membrane pro-
teins of C. jejuni have been found to be N-glycosylated.
Inhibition of key enzymatic steps in each pathway blocks the
addition of glycans to target proteins. In the N-glycosylation
(Pgl) pathway, the oligosaccharyltransferase PglB is critical for
transfer of the final glycan to the target protein in the periplasm.
Deletion of pglB had no detectable impact on bacterial binding
to any of the examined BgAgs (figure 3a), indicating that the
N-glycosylation system does not influence BgAg binding.
The predominant O-glycans attached to the Campylobacter
flagellum are derivatives of pseudaminic acid (Pse) or legionami-
nic acid (Leg), which are C9 sugars related to sialic acids [32].
Mutation of pseD, which encodes a putative PseAm transferase,
results in a fully motile phenotype [19,33], but with a loss of
PseAm from the flagellin [19]. Mutation of pseD resulted in a sig-
nificant reduction in the binding of NCTC11168 to all examined
BgAgs (figure 3b), suggesting that O-glycosylation of BgAg
ligands is required for optimal BgAg binding. Intriguingly,
when MOMPs purified from NCTC11168 and 11168DpseD
were compared by immunoblotting, the latter exhibited an
apparent size shift compared with MOMP from the wild-
type strain, consistent with the loss of glycan modifications
(figure 3c) and reminiscent of the size shift seenwhen comparing
glycosylatedandunglycosylated flagellinproteins [31].We there-
fore hypothesized that, in addition to flagellin proteins, MOMP
may also be O-glycosylated. To address this, MOMP from
NCTC11168 was analysed by Nanoflow LC-MS/MS FT/ICR
following in-gel protein digestion as described by Shevchenko
et al. [34]. The MS/MS analysis showed that a peptide corre-
sponding to amino acids 268–278 of NCTC11168 MOMP was
glycosylated; specifically, the amino acid Thr268 was carryingHex-(HexN-acetylamine)3 (where Hex can be glucose or galac-
tose; figure 4a–c). To confirm that Thr268 was indeed the amino
acid residue targeted by the O-glycosylation system, we substi-
tuted Gly for Thr268 yielding a MOMP268T/G derivative in
NCTC11168. This substitution had no deleterious effect on
in vitro growth (data not shown), but the apparent size of the
11168 MOMP268T/G protein was distinct from that of wild-type
MOMP and indistinguishable from that of MOMP purified
from 11168DpseD (figure 3c), confirming that Thr268was glycosy-
lated in the wild-type protein, the glycosylation was responsible
for the altered electrophoretic mobility and that PseD was
required for this modification. Nanoflow LC-MS/MS FT/ICR
analysis of purified MOMP268T/G confirmed the absence of the
Hex-(HexN-acetylamine)3 glycosylation.3.4. O-Glycosylation of NCTC11168 MOMP effects
BgAg binding
The ability of the MOMP268T/G mutant to bind to a range of
BgAgs in ELISA assays was examined, along with a double
mutant strain in which flaA had also been inactivated. The
MOMP268T/G substitution significantly reduced BgAg binding
(figure 4d). To rule out polar effects linked to the insertion of a
kanamycin resistance cassette at the endof porA (used to facilitate
selection for the MOMP268T/G substitution), we also constructed
11168-Kan, which contains the resistance cassette at the porA
locus but without the substitution. This strain showed no
significant difference in BgAg-binding activity compared with
NCTC11168 (figure 4d).
3.5. NCTC11168 MOMP glycosylation is an O-linked
trimeric form of T-antigen
Lectin binding was used for further characterization of
the O-glycan attached to NCTC11168 MOMP. Seven different
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Figure 2. FlaA and MOMP are required for C. jejuni BgAg binding.
(a) NCTC11168 and its DflaA mutant derivative were examined for binding
to Leb, H-II, H-I and Lea. Binding of 11168DflaA was significantly reduced com-
pared with the wild-type (*p, 0.05; **p, 0.01). Error bars: mean of
triplicate values+ s.e.m. from three independent experiments. (b) Binding
of NCTC11168 to H-II glycoconjugate in the absence of inhibitor (non-treated,
NT) or after H-II coated plates were treated with purified NCTC11168 MOMP
before the addition of bacteria or after NCTC11168 were pre-incubated with
H-II glycoconjugate (H-II). ***significantly reduced compared with non-treated
( p, 0.001). Error bars: mean of triplicate values+ s.e.m. from three
independent experiments.
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supplementary material, table S4) were tested. Purified
NCTC11168 MOMP showed significant binding to the lectins
Jacalin [35] and, to a lesser extent, DSL and LEL (figure 5a).
Among the galactose-specific lectins, Jacalin exhibits speci-
ficity for human tumour-specific Thomsen-Friedenreich
disaccharide (T-antigen; Gal(b1–3)-GalNAca1-Ser/Thr)
[36]. To confirm that the Jacalin binding was the result of
O-glycosylation of amino acid Thr268, MOMPs purified
from NCTC11168 and NCTC11168 MOMP268T/G were
probed with monoclonal anti-T-antigen in ELISA assays
(figure 5b). Both the antibody and Jacalin lectin bound
strongly to MOMP purified from NCTC11168; significant
reduced binding was observed to MOMP268T/G (figure 5b).
Combined with the previous MS/MS analysis suggesting
a Hex-(HexN-acetylamine)3 glycan, our lectin-binding analy-
sis indicates that the MOMP glycan in NCTC11168 is likely
to be the O-linked trimeric form of T-antigen: Gal(b1–3)-
GalNAc(b1–4)-GalNAc(b1–4)-GalNAca1-Thr268 (electronic
supplementary material, figure S1).3.6. Modelling the structure of glycosylated and
non-glycosylated NCTC11168 MOMP
Although Gram-negative bacterial porins show considerable
diversity in their primary sequences, they are remarkably
similar in their secondary and tertiary structure, in which
beta strands combine to form a trans-membrane beta-barrel
structure [37]. CD spectroscopy analysis demonstrated that
the folded MOMP monomer mainly comprised b-sheet
secondary structure [38]. Accordingly, two-dimensional crys-
tallographic analysis showed that MOMP is structurally
related to the family of trimeric bacterial porins [39]. Here,
we utilized the beta-barrel structure of the anion-selective
porins of Comamonas acidovorans (1E54.pdb) and Pseudomonas
aeruginosa (2QTK.pdb) as templates to construct a model of
C. jejuni NCTC11168 MOMP. The lowest energy structures
of glycosylated and non-glycosylated MOMP at 300 K were
calculated; these comprised nine loops and 18 beta strands
(figure 6a). The structures of non-glycosylated MOMP and
MOMP glycosylated at residue 268 were calculated and
superimposed (figure 6b,c); the modification was predicted
to result in major conformational changes affecting loops 4,
6 and 7 (corresponding to amino acids 169–200, 256–274
and 296–333, respectively); thus we hypothesized that the
O-glycosylation of MOMP leads to conformation changes in
the molecule which might favour BgAg binding. In addition,
further simulations showed that the protein has a canal-like
cavity, which is expected to be capable of accommodating
very large molecules. However, non-glycosylated MOMP
has a larger cavity compared with its glycosylated form
(figure 6d,e).3.7. Modelling NCTC11168 MOMP–BgAg interactions
To further support our hypothesis, Leb (as an example of a
type-1 Lewis antigen) and H-II (as an example of a type-2
antigen; electronic supplementary material, figure S2)
were docked into the central channel-forming cavity of
NCTC11168 MOMP predicted in the model structures of gly-
cosylated MOMP (figure 7a and d, respectively) and the
complexes computed in molecular dynamics (MD) [9] simu-
lations. Interestingly, the predicted interaction between the
galactose residues with Arg328 is broken in the complex of
MOMP and H-II, in which the region containing the glycosy-
lated residue moves towards loop 4 resulting in a new
interaction with the residues Thr186 and Thr187. A similar con-
formational change was not predicted when the interaction
between glycosylated MOMP and Leb was modelled. The
average energies derived from MD simulations of complexes
are listed in the electronic supplementary material, table S5.
The introduction of the ligands leads to conformational
changes affecting the longest of the predicted loops (loops 4
and 7) in particular. It was found that the predicted glycosy-
lated MOMP structure was relatively stable compared with
the non-glycosylated form, with only loop 7 predicted to
undergo marked conformational changes when glycosylated
MOMP is complexed with BgAgs. This prediction suggests
that glycosylation enhances the stability of the protein.
Figure 7 highlights the residues of glycosylated and non-
glycosylatedMOMP contributing to the interaction of these pro-
teins with Leb (b and c, respectively) and H-II (e and f,
respectively). It is apparent that the glycosylated MOMP has
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Figure 3. O-Glycosylation but not N-glycosylation modulates C. jejuni BgAg binding. (a) NCTC11168 and 11168DpglB were examined for binding to core-II, core-I,
H-I, H-II, Leb, Lex and Ley. Binding was not significantly reduced following pglB mutation. Error bars: mean of triplicate values+ s.e.m. from three independent
experiments. (b) NCTC11168 and 11168DpseD were examined for binding to core-II, H-I, H-II, Leb and Ley. The binding of 11168DpseD was significantly reduced
compared with the wild-type (***p , 0.001). Error bars: mean of triplicate values+ s.e.m. from three independent experiments. (c) Immunoblot analysis of
purified MOMP from wild-type NCTC11168, 11168MOMP268T/G and 11168DpseD strains using anti-MOMP antibodies. MOMP from the latter two strains showed
an apparent size shift compared with the wild-type protein indicating a loss of glycosylation.
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version. Specifically, the residues Arg352, Lys278 and Lys385 are
predicted to be major contributors to the interaction of the gly-
cosylated protein with Leb via hydrogen bonds, whereas only
the residues Asn258 and Lys278 of non-glycosylated MOMP
are predicted to interact with Leb. Residues Arg352 and Lys385
are both within loop 7, which is predicted to be more suscep-
tible to conformation changes as a result of glycosylation or
interaction with BgAgs in MD simulations (figure 7b). Incorpor-
ation of the glycosyl group with this loop thus appears to
stabilize a conformation that favours interaction with Leb.
Calculations also show that the glycosylated protein
has more favourable van der Waals interactions compared
with the non-glycosylated protein: the residues Leu290,
Tyr294, Phe395 and Ile337 are located over the hydrophobic sur-
face of Leb in the complex of glycosylated MOMP but not in
the complex with non-glycosylated MOMP (figure 7b and c,
respectively). This is reflected in a 67 kcal mol21 van der
Waals energy difference between the two complexes. H-II is
predicted to be bound to both versions of the protein in a simi-
lar manner to Leb. The residues Lys278, Arg352 and Arg381 are
involved in the complex of both glycosylated and non-glyco-
sylated MOMP with H-II (figure 7e and f, respectively). The
two complexes differ in that residue Asp261 contributes to
the interaction of H-II with non-glycosylated MOMP, but not
glycosylated MOMP, whereas the reverse is true for Ser397.
MD calculations also show that active sites of the glycosylated
and non-glycosylated proteins have different conformational
orientations with respect to the two ligands.We attempted to substitute five amino acids (S262-G,
K278-G, R352-G, R381-G and S397-Y) within the predicted
binding site of NCTC11168 MOMP (singly or in various com-
binations) but were unable to do so, suggesting perhaps that
these amino acid residues are important for MOMP stability
and thus function. Overall, our modelling confirms that the
O-glycosylation of MOMP favours BgAg binding.3.8. O-Glycosylation of NCTC11168 MOMP effects
auto-agglutination, biofilm formation,
adherence to Caco-2 cells and chicken
colonization
Loss of O-glycans, for example PseAm, from C. jejuni flagellins
has previously been shown to affect the ability of the organism
to auto-aggregate, form biofilms, adhere to and invade mono-
layers of INT407 cells and cause disease in in vivo models of
infection [19]. We therefore hypothesized that loss of the
MOMP O-glycan may also lead to similar effects. As expected,
11168MOMP268T/G had a significant reduced propensity to
auto-agglutinate or form biofilms compared with wild-type
(figure 8a and b, respectively). Furthermore, the addition of
soluble BgAgs to the culture media led to reduced biofilm for-
mation by NCTC11168, suggesting that BgAgs compete with
biofilm determinants on flagellin and MOMP (see electronic
supplementarymaterial, figure S3). Additionally, pre-treatment
of Caco-2 cells with purified glycosylated MOMP (but not
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Figure 4. Overview of the LC-MS/MS analysis of NCTC11168 MOMP and confirmation of the role of Thr268 glycosylation in BgAg binding. (a) Base peak chromato-
gram: tryptic peptides are loaded on an online coupled C18 column and eluted into the mass spectrometer for analysis. (b) MS precursor scan of the double charged
glycosylated peptide at m/z 978.91. (c) CID-MS/MS spectrum of the selected ion. (d ) Substitution of the glycosylation site in NCTC11168 MOMP (Thr268 to Gly) was
achieved and the binding to Leb, H-II and H-I was examined. Also included was a double mutant (DM) in which flaA was also inactivated and 11168-Kan, which
contains the resistance cassette at the porA locus but without the substitution. Compared with wild-type, BgAg binding was significantly reduced in both
11168MOMP268T/G and 11168-DM strains. 11168-Kan showed no significant difference in BgAg-binding activity compared with NCTC11168. Error bars: mean of
triplicate values+ s.e.m. from three independent experiments. *p , 0.05; **p, 0.01; ***p, 0.001.
rsob.royalsocietypublishing.org
Open
Biol.4:130202
6
 on July 8, 2016http://rsob.royalsocietypublishing.org/Downloaded from MOMP268T/G) significantly inhibited the association of
wild-typeNCTC11168 to Caco-2 cells (figure 8c), which express
H-I, H-II and Leb BgAgs [40]. Adherence of 11168MOMP268T/G
to Caco-2 cells was significantly reduced compared with wild-
type NCTC11168. Levels of 11168MOMP268T/G adhesion were
unaffected by the pre-treatment of Caco-2 cells with either
MOMP derivative (figure 8c).
Finally, the ability of 11168MOMP268T/G to colonize chick-
ens was determined. To do this, six-week-old birds (n ¼ 10
per group) were challenged with 3  103 cfu wild-type strain
NCTC11168-O (a robust colonizing strain, derived from
NCTC11168 by passage through chicken) or its 11168-O
MOMP268T/G mutant by oral gavage. Caecal colonizationlevels were determined in birds from each group at 7 days
post-challenge. The results showed a significant reduction in
the geometric mean colonization levels in the caeca and liver
in the MOMP268T/G group compared with the wild-type
(figure 8d). These results confirm the importance and biological
relevance of MOMP O-glycosylation in the establishment of
colonization in vivo.4. Discussion
There is currently a need for a better understanding of the
pathogenic mechanisms underlying the infection of humans
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Figure 5. Detection of glycan constituents of purified MOMP from NCTC11168 using biotinylated labelled lectins and antibodies against glycans. (a) Binding of the
following glycans: GSL II, Griffonia (Bandeiraea) simplicifolia lectin II; DSL, Datura Stramonium lectin; ECL, Erythrina cristagalli lectin; LEL, Lycopersicon esculentum
(tomato) lectin; STL, Solanum tuberosum ( potato) lectin; VVA, Vicia villosa agglutinin; and Jacalin, Artocarpus integrifolia lectin to immobilized NCTC11168 MOMP
was investigated using ELISA. Jacalin lectin showed the greatest degree of binding to NCTC11168 MOMP. Jacalin lectin specifically recognizes Gal(b1–3)-GalNAca1-
Ser/Thr (T-antigen). (b) ELISA confirmation using anti-T-antigen monoclonal antibody or Jacalin lectin to confirm that the glycan detected on NCTC11168 MOMP was
T-antigen. 11168MOMP268T/G showed significantly reduced binding to either Jacalin lectin or anti-T antigen compared with NCTC11168 MOMP. Error bars: mean of
triplicate values+ s.e.m. from three independent experiments. ***p, 0.001.
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C. jejuni. Here, we confirm that C. jejuni, like H. pylori, can
bind to BgAgs and to the lacto series type I and II, a charac-
teristic that is likely to contribute to the ability of this
intestinal bacterium to interact with epithelial cells lining
the gastrointestinal tract. The high degree of specificity exhib-
ited by H. pylori in its BgAg-binding interactions [28,29] is in
contrast to our findings, and those of Day et al. [23], showing
that C. jejuni can bind to a wide range of related antigens.
This may reflect the contrast between the very restricted
host range of H. pylori, which infects only humans, and that
of C. jejuni, which is able to establish infection in a wide
range of birds and mammals. The latter may thus have
gained an evolutionary advantage by broadening its speci-
ficity and thus maximizing its survival in different hosts.
Whether C. jejuni can bind to non-human BgAgs, especially
those expressed by chickens, remains to be experimentally
confirmed, although our in vivo data suggest that this is a
possibility since a C. jejuni derivative lacking the MOMP
O-glycan (and hence exhibiting reduced BgAg-binding)
showed a significantly reduced ability to colonize chickens.
Identification of both FlaA and MOMP as BgAg-binding
adhesins was surprising as these proteins have little in
common in terms of their primary sequence, predicted struc-
ture or known functions. FlaA is the major structural subunit
of the flagellum and is thus required for motility. Intact and
fully functional flagella are required for the colonization of
chickens, invasion into human epithelial cells and transloca-
tion of human intestinal cell monolayers [41–43]. MOMP is
a member of the trimeric bacterial porin family and forms
voltage-sensitive cation-selective ion channels [44]. It is pre-
dicted to comprise outer membrane-spanning beta strands
separated by short periplasmic and longer surface-exposed
loops [30]. In addition to its porin functions, MOMP has
been shown to bind to the surface of human epithelial cells
and to the basement membrane protein fibronectin [45].Interestingly, it shares this latter property with FlaA, as
well as the outer membrane protein CadF [45]. Thus, both
MOMP and FlaA appear to mediate binding to multiple
host cell molecules, which now includes BgAgs. MOMP is
encoded by the porA gene, which is extremely genetically
diverse with most variation occurring in regions encoding
surface loops (particularly loop 4), suggesting that immune
selection strongly influences the diversity of the MOMP
protein [46].
Campylobacter flagella and numerous surface proteins are
post-translationally decorated with glycan molecules [47].
This led us to hypothesize that, like FlaA, MOMP is glycosy-
lated, and that BgAg binding by these two diverse ligands
may be influenced by the presence of surface glycans.
Campylobacter jejuni harbours both N- and O-linked glycosyla-
tion systems [47]. The genes known to contribute to the O-
glycosylation of C. jejuni flagellin are clustered in the flagellar
glycosylation locus [19]. We have demonstrated that, like fla
gellin, MOMP is also O-glycosylated, the first demonstration
that a non-flagellin protein is glycosylated by this system.
Our results also demonstrate that the MOMP O-glycan con-
tains an epitope which mimics a GM1 ganglioside epitope:
Gal(b1–3)-GalNAc(b1–4)-Gal-[Neu5Aca2–3]-(b1–4)-Glcb1-
ceramide. As MOMP is highly immunogenic, the expression
of a glycosylated form of MOMP may play a hitherto under-
appreciated role in the development of autoimmune diseases,
for example GBS. This potentially significant finding requires
further experimental consideration.
Our finding that MOMP is O-glycosylated may provide
an explanation for a recent observation made by Hitchen
et al. [48]. They showed that the product of the phase variable
gene Cj1295 in C. jejuni NCTC11168 was responsible for the
modification of Pse residues present on flagellins with di-O-
methyl-glyceric acid [48]. Immunoblots of whole-cell extracts
using rabbit polyclonal anti-flagellin antibodies showed
the differing electrophoretic mobilities of flagellin with or
(a)
(c) (d) (e)
(i) (ii)
(b)
L8
L9
L6
L2
L5
L3
L1
L7
L4 glycan
outside
outer
membrane
periplasm
Figure 6. Three-dimensional model of MOMP. (a) Non-glycosylated (i) or glycosylated (ii) at Thr268 (loop 6) of NCTC11168 MOMP embedded in the outer mem-
brane. Approximate boundaries of the hydrophobic regions of the proteins predicted to be embedded in the outer membrane are represented by horizontal lines.
(b) The superimposed lowest energy structure of non-glycosylated MOMP on the lowest energy structure of glycosylated MOMP (magenta) with RMSD of 1.291.
Loops are shown in the following colours: b strands are green; L1 (residues 41–60), red; L2 (residues 87–109), magenta; L3 (residues 128–147), orange; L4
(residues 169–200), yellow; L5 (residues 227–233), black; L6 (residues 256–274), blue; L7 (residues 296–333), grey; L8 (residues 360–379), cyan; L9 (residues
399–414), purple. (c) Superimposed surface representation of the structures of non-glycosylated MOMP (grey) on its glycosylated form (magenta) viewed from the
external face. Surface representation of the structures of non-glycosylated MOMP (d ) and its glycosylated form (e), viewed from the external face.
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antibodies also detected one additional protein: a 45 kDa
protein, subsequently identified as MOMP [48]. The detection
of MOMP using anti-flagellin was suggested to be due to
non-specific binding [48]. However, in light of our data con-
firming the O-glycosylation of MOMP, we hypothesize that
the cross-reactivity is due to the presence of shared epitopes,
likely to be shared or similar O-glycan determinants. We are
currently investigating possible similarities between the
MOMP and flagellin O-glycan repertoires.
Having shown glycosylation, we identified T268 as the
target for the O-glycosylation of MOMP in strain NCTC
11168; this residue is within the sixth predicted surface-
exposed loop, but is conserved in only 25 of the 46 sequences
examined (see electronic supplementary material, figure S4).
These included six clinical isolates tested for their ability to
bind BgAgs: three high BgAg binders and three isolates
with low BgAg-binding activity. T268 was conserved in all
three high binders, but also in two of the three low binders.
Previously, Seal et al. [49] reported that arginine wassubstituted for T268 in the MOMP sequence of the isolate
A74/C compared with NCTC11168-PMSRU. The latter, a
derivative of strain NCTC11168, was described as a poor
chicken colonizing strain, while the former was described as
a robust colonizer [49]. Changes in the isoelectric point of
MOMP were among the differences reported between these
two isolates, while the apparent molecular mass (as judged
by electrophoretic mobility in SDS-PAGE gels) was indistin-
guishable between the two proteins. This is in contrast to
our findings, where the substitution of glycine for T268 resulted
in a distinct mobility shift that was indistinguishable from that
observed in MOMP isolated from a pseD mutant. It is notable
that the only other substitution in the A74/CMOMP sequence
with respect to the NCTC11168 sequence was threonine for
R367, a residue predicted to reside within the eighth surface-
exposed loop according to the model proposed by Zhang
et al. [30]. It is tempting to speculate that threonine at position
367 (numbering corresponding to the NCTC11168 sequence)
may be an alternative site for O-glycosylation. Of the isolates
examined, eight of the 46 (17%) harboured a threonine at
(a) (d)
(b)
(c) ( f )
(e)
Figure 7. Influence of glycosylation on conformational changes induced by ligand binding. A stereo cartoon of the MOMP backbone viewed from the extracellular
side is presented. Regions are shown in the following colours: green (b strands); red (L1); magenta (L2); orange (L3); yellow (L4); black (L5); blue (L6); grey (L7);
cyan (L8); purple (L9). The complexes are with Leb (a) and H-II (d ). In addition, hydrogen bonds shown in light blue correspond to amino acids residues, which are
putatively involved in the interactions of glycosylated MOMP (b and e) and its non-glycosylated form (c and f ) with Leb and H-II, respectively, in their active sites.
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268 or 367. Whether threonine at this position or indeed at
other positions within variant MOMP proteins are targets for
the O-glycosylation system remains to be determined. All of
the C. jejuni clinical isolates tested bound to at least some of
the BgAgs, but the degree of binding was highly variable; vari-
ations in MOMP primary sequence and perhaps the presence
of specific targets for the O-glycosylation system are likely to
account for at least some of this variation. Likewise, variable
O-glycosylation of FlaA may also account for variations in
BgAg binding between strains.It remains to be determined whether the bacterial
O-glycans exert a direct (i.e. bacterial glycan to host glycan)
or indirect effect on BgAg binding. However, based on our
molecular modelling data, our favoured hypothesis is that
the effect is indirect, whereby the presence of O-glycans results
in conformational changes or stabilization of particular confor-
mations of the bacterial ligands, which favour BgAg binding.
Identification of protein glycosylation profiles of C. jejuni,
especially those related to outer membrane proteins, is
fundamental for understanding the diverse pathogenicity of
C. jejuni strains among different hosts. The model for
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Figure 8. O-glycosylation of MOMP effects auto-agglutination, biofilm formation, adherence to Caco-2 cells and chicken colonization. (a) The ability of
11168MOMP268T/G to auto-agglutination was significantly reduced compared with wild-type 11168 ( p, 0.0001). 11168DflaA was used as a negative control
for aggregation. Error bars (too small to be seen) ¼ mean of triplicate values on three occasions+ s.e.m. (b) Similarly, the ability of 11168MOMP268T/G to
form biofilms was significantly reduced compared with wild-type NCTC11168. 11168DflaA was used as a negative control for biofilm formation. Error bars ¼
mean of triplicate values on three occasions+ s.e.m. *p, 0.05; ***p, 0.001. (c) Binding of NCTC11168 and 11168MOMP268T/G to Caco-2 cells in the absence
of inhibitor (non-treated, NT) or following pre-treatment of Caco-2 cells with purified MOMP or MOMP268T/G. *Significantly reduced compared with the binding of
non-treated NCTC11168 ( p, 0.05). Error bars: mean of triplicate values+ s.e.m. from three independent experiments. (d ) Colonization of chickens by NCTC11168-
O and 11168-O MOMP268T/G mutant 7 days post-infection. The geometric mean colonization levels in caeca are significantly reduced ( p, 0.0001) and are below
the limit of detection (102cfu g21) in 8/10 birds inoculated with 11168-O MOMP268T/G. Similarly, levels of 11168-O MOMP268T/G mutant in the liver were below the
limit of detection in 10/10 birds 7 days post-infection.
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MOMP generated here substantially increases our knowledge
about the protein and its interactions. The identification of
BgAgs as receptors for the adhesive function of MOMP and
the mapping of the binding site could inform vaccine
design. Attempts to develop vaccines have met with little
success, and concerns about the possible induction of autoim-
munity-associated pathologies, for example GBS, are a barrier
to the development of whole-cell vaccines for use in humans
[50]. An alternative approach is to use epitopes that play an
important role in colonization; glycosylated peptides would
constitute particularly attractive targets for such an approach
as they may be under selective pressure to be maintained,
and neutralizing antibodies may reduce the ability of the
pathogen to colonize the host. Immunization experiments
with adhesins of uropathogenic Escherichia coli demonstrate
the potential in the generation of antibodies with adhesion
inhibitory properties [51]. Also, Houpt et al. [52] describedan effective vaccine against intestinal Entamoeba histolytica
infection using amoebic Gal/GalNAc lectin, which blocks
both invasive disease and parasite transmission. Though
the potential for developing vaccines against C. jejuni for
use in humans may be limited, vaccines targeted at animal
hosts of C. jejuni, particularly chicken, represent a promising
approach to the reduction of C. jejuni contamination of poul-
try, and thus indirectly human infection. In a study by Huang
et al. [53], vaccination of chickens with recombinant MOMP
reconstituted in proteoliposomes demonstrated confor-
mation-dependent humoral responses to MOMP, which
confirms our finding that any modification of MOMP has
important implications for protein conformation and may
alter MOMP immunogenicity. The stereochemical fit of the
molecular interaction between microbial adhesins and host
receptors determines in part tissue tropism during the
colonization process. The possibility of interfering with
such interactions provides new approaches to the
rsob.royalsocietypublishin
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early stage of colonization. Anti-adhesive receptor analogues
may prove to be a viable strategy for lowering colonization
levels in poultry.
In summary, this work provides key new insights into
C. jejuni pathogenesis and, importantly, illustrates how glyco-
sylation of outer membrane proteins dynamically furnishes
C. jejuni with features that are of importance for the
bacterial–host crosstalk during infection in the human host. g.org
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5.1. Bacterial strains and growth conditions
Escherichia coli strain JM109 was used as a host strain for the
construction of mutagenic constructs (see electronic
supplementary material, table S6). E. coli strains were
grown in Lysogeny broth supplemented with ampicillin
(100 mg ml21), kanamycin (50 mg ml21) or chloramphenicol
(20 mg ml21). Campylobacter jejuni NCTC11168 and most of
the clinical isolates used in this study were kindly provided
by Prof. J. Ketley (University of Leicester, UK; electronic sup-
plementary material, table S2), with the remaining clinical
isolates being obtained from the Department of Clinical
Microbiology, Nottingham University Hospitals NHS Trust,
Nottingham, UK (see electronic supplementary material,
table S2). All C. jejuni strains were grown under microaero-
philic conditions at 378C on modified CCDA agar (Oxoid),
or in Mueller–Hinton broth (Oxoid) supplemented with
kanamycin (50 mg ml21) and chloramphenicol (20 mg ml21)
where appropriate.
5.2. Digoxigenin labelling of bacteria
DIG-labelling was carried using the Roche DIG-NHS Protein
labelling kit, used as per manufacturer’s instructions. Briefly,
cells were harvested from an overnight plate and washed
three times in sodium carbonate buffer (142 mM NaHCO3,
8 mM Na2SO3, pH 9.0). Bacteria were resuspended to an opti-
cal density at 600 nm (OD600) of 1.0 and then labelled with
10 mg DIG-NHS at room temperature for 1 h. Cells were
then washed three times in PBS with 0.05% Tween 20 (PBS-
T) and resuspended in PBS containing 1% bovine serum
albumin (1% BSA/PBS).
5.3. ELISA
BSA–BgAg conjugates were obtained from IsoSep, Tullinge,
Sweden. Coupling of BgAgs to 96-well plates (NUNC
Immobilizer Amino) was carried out by the addition of
100 ml BSA–BgAg (5 mg ml21 unless stated otherwise) in
sodium carbonate buffer to each well. Plates were incubated
at room temperature for 2 h before unbound reagent was
removed by washing three times in PBS-T. All wells were
blocked by the addition of 100 ml 1% BSA/PBS and incu-
bated for 2 h at room temperature. After further washing in
PBS-T, 100 ml of DIG-tagged bacteria (at OD600 of 0.05
unless stated otherwise) were added to each well and incu-
bated overnight at 48C. Plates were washed three times in
PBS-T before 100 ml anti-digoxigenin-POD solution (Roche
Diagnostics; 1 in 5000 diluted in 1% BSA/PBS) was added
and incubated for 1 h at room temperature. Plates wereagain vigorously washed in PBS-T and colour developed by
adding 100 ml ABTS substrate (Roche). Plates were read
with an ELISA reader (Biotek EL800) at an absorbance of
405 nm. Specific binding was determined by subtracting the
binding of each strain to BSA (typically OD405 0.07–0.09)
from the binding to each BSA–BgAg conjugate. Statistical
significance was determined using Student’s t-test. Inhibition
assays were carried out as above but after the removal of the
blocking solution, 100 ml purified MOMP (5 mg ml21 in 1%
BSA/PBS) was added to each well and incubated at 48C over-
night. Alternatively, DIG-labelled C. jejuni were pre-
incubated for 4 h with BgAgs (20 mg ml21) in 1% BSA/PBS
before being added to each well.
5.4. Re-tagging
NCTC11168 (1 ml of OD600 0.25) was incubated for 5 h with
BSA conjugated to Leb, H-II or H-I (20 mg) (or BSA alone as
control) to which the Sulfo-SBED cross-linker (Pierce) had
been conjugated according to the manufacturer’s recommen-
dations. Following washing in PBS-T, the photo-reactive
cross-linker group was activated by 10 min exposure to ultra-
violet irradiation (365 nm). Samples were then incubated
under reducing conditions (50 mM dithiothreitol) for
10 min, washed with PBS-T and boiled three times for
5 min with 10 min intervals between boiling. Biotin-(re)tagged
proteins were then purified with streptavidin-coated magnetic
beads as previously described [28]. Extracted biotin-tagged
proteins were separated by SDS-PAGE and bands digested
with sequencing-grade trypsin (Promega) and analysed using
a Micromass Tof-Spec E (Micromass).
5.5. Mutagenesis
To mutate flaA, a 5.58 kb fragment encompassing the flaA locus
was amplified from C. jejuni NCTC11168 using primers
FLAAF1 and FLAAR1 (see electronic supplementary material,
table S7) using the Expand High Fidelity PCR system (Roche).
The resulting amplicon was ligated into pGEM-T Easy accord-
ing to the manufacturer’s protocol to yield pNJO83
(see electronic supplementary material, table S6). This was
subjected to inverse PCR using primers FLAAR2 and
FLAAINV5 (see electronic supplementary material, table S7)
resulting in an amplicon in which the flaA gene was deleted
and containing a unique BamHI site which was used to intro-
duce the chloramphenicol resistance cassette from pAV35 in
place of the deleted gene. The resulting plasmid, pJS101, was
confirmed by sequencing before being used to mutate
C. jejuni by electro-transformation and allelic exchange as
described previously [54]. To mutate pglB, chromosomal
DNA extracted from C. jejuni 81–176DpglB (obtained from
Prof. J. Ketley, University of Leicester, UK) was used to
mutate NCTC11168 by natural transformation and allelic
exchange as described previously [54]. To mutate pseD, a
3.9 kb fragment encompassing the pseD gene was amplified
from NCTC11168 template DNA using primers Cj1333_F and
Cj1333_R2 (see electronic supplementary material, table S7).
The resulting amplicon was ligated into pGEM-T Easy to
yield plasmid pKG352 (see electronic supplementary
material, table S6). The pseD gene was deleted from this plas-
mid by inverse PCR amplification using primers Cj1333_M1
and Cj1333_M3 (see electronic supplementary material,
table S7) and the resulting amplicon digested with BglII
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supplementary material, table S6). Plasmid pKG353 was
digested with BglII and ligated to a kanamycin resistance cas-
sette obtained by the digestion of pJMK30 (see electronic
supplementary material, table S6) with BamHI. A resulting
plasmid containing the kanamycin resistance cassette in the
reverse orientation to the deleted pseD gene was designated
pKG354 (see electronic supplementary material, table S6)
and used to mutate NCTC11168 as described above. To con-
struct MOMP268T/G, a 2 kb region spanning porA was
amplified from C. jejuni NCTC11168 using MOMPF4 and
MOMPR4 (see electronic supplementary material, table S7)
and cloned into pGEM-T Easy to yield pNJO76 (see electronic
supplementary material, table S6). This construct was used as
template for inverse PCR using MOMPF3 and MOMPR3,
which introduced a unique BglII site in the intergenic region
between porA and dnaJ into which the kanamycin cassette
from pJMK30 could be introduced. The resulting plasmid,
pNJO78, was confirmed by restriction digestion and sequen-
cing before being used to mutate NCTC11168 by electro-
transformation and allelic exchange to create 11168-Kan.
pNJO78 was also used as template for the QuikChange Site-
Directed mutagenesis kit (Stratagene). SDMOMP1 and
SDMOMP2 primers (see electronic supplementary material,
table S7) were designed to substitute the threonine at position
268. The resulting plasmid, pSD, was confirmed by sequencing
before being used to mutate C. jejuni by electro-transformation
and allelic exchange. Mutants lacking flaA in the MOMP268T/G
genetic background were created by electro-transforming this
mutant with pJS101 (see electronic supplementary material,
table S6). All mutants were confirmed by PCR and DNA
sequencing (data not shown).
5.6. Purification of Campylobacter jejuni
MOMP and generation of rabbit anti-MOMP
antiserum
CampylobacterMOMP was purified to homogeneity according
to a previously described method [38]. New Zealand White
female rabbits were immunized subcutaneously three times
at two-week intervals with 30 mg of purified NCTC11168
MOMP emulsified in Freud’s complete (first immunization
only) or incomplete adjuvant. Rabbit anti-MOMP antisera
was used in immunoblotting experiments 1 : 5000 diluted in
blocking buffer (1% BSA in PBS-T) and incubated for 2 h.
After washing three times in PBS-T, membranes were
incubated for 2 h with goat anti-rabbit IgG–alkaline phos-
phatase conjugate (Sigma), at a dilution of 1 : 2000 in
blocking buffer. After washing with PBS-T, the blots were
developed using BCIP/NBT-Blue liquid substrate (Sigma).
5.7. Identification of glycopeptides from purified MOMP
MOMP was purified under non-denaturing conditions and
analysed by Nanoflow LC-MS/MS FT/ICR following in-gel
protein digestion as previously described [34]. Briefly,
the gel pieces were destained by washing three times in
25 mM NH4HCO3 in 50% CH3CN and once in 25 mM
NH4HCO3 in 50% CH3OH. Gel pieces were dried in a
vacuum centrifuge and incubated with digestion buffer
(50 mM NH4HCO3, 10 ng ml
21 trypsin) at 378C overnight.
Peptides were extracted in 50% CH3CN/1% CH3COOHand the supernatant was evaporated to dryness in a
vacuum centrifuge. Prior to MS analysis, the peptides were
reconstituted in 0.2% HCOOH. After digestion, samples
were subjected to LC-MS/MS analysis using a hybrid linear
ion trap-FTICR mass spectrometer operated in data-depen-
dent mode, automatically switching to MS/MS mode. MS-
spectra were acquired in the FTICR, while MS/MS-spectra
were acquired in the LTQ-trap. For each FTICR scan, the six
most intense, double-, triple- and quadruple-charged, ions
were sequentially fragmented in the linear trap by collision-
induced dissociation. All tandem mass spectra were searched
by MASCOT (Matrix Science, London, UK) against the Swiss-
Prot database (release 54.0). Glycan structure and position
were determined by the manual interpretation of the CID
fragmentation spectra, using the XCALIBUR software v. 2.0.7
(Thermo Scientific).
5.8. Detection of glycoproteins using lectins or
anti-T antigen
Microtitre plates (NUNC Immobilizer Amino) were coated
with NCTC11168 MOMP by placing 5 mg ml21 glycoprotein
in sodium carbonate buffer in each well. Untreated wells
were used as negative controls. Plates were incubated at
378C for 1 h, before being washed three times with PBS-T.
Non-specific binding was blocked by adding 1% BSA/PBS
to each well for 30 min at room temperature. Plates were
then washed three times with PBS-T, before 3 mg ml21 biotin-
ylated lectins (Vector) or anti-T antigen (1 : 5000) in PBS were
added and incubated for 30 min at room temperature. Fol-
lowing further washing with PBS-T, avidin–biotin-complex
(peroxidase) was added according to the kit instructions
and incubated for 30 min at room temperature following by
washing three times with PBS-T. Finally, 100 ml of ABTS
was applied and plates were read with an ELISA reader
(Biotek EL800) at an absorbance of 405 nm.
5.9. Computational modelling
All molecular dynamic simulations were conducted by using
the AMBER (v. 10.0) suite of programs on the Linux/Intel PC
cluster of TR-Grid maintained by TUBITAK (Scientific and
Technologic Research Council of Turkey). We initiated our
simulations using the following amino acid sequence:
MKLVKLSLVAALAAGAFSAANATPLEEAIKDVDVSGV
LRYRYDTGNFDKNFVNNSNLNNSKQDHKYRAQVNFSAA
IADNFKAFVQFDYNAADGGYGANGIKNDQKGLFVRQLYL
TYTNEDVATSVIAGKQQLNLIWTDNAIDGLVGTGVKVVN
NSIDGLTLAAFAVDSFMAAEQGADLLEHSNISTTSNQAPF
KVDSVGNLYGAAAVGSYDLAGGQFNPQLWLAYWDQVAF
FYAVDAAYSTTIFDGINWTLEGAYLGNSLDSELDDKTHAN
GNLFALKGSIEVNGWDASLGGLYYGDKEKASTVVIEDQG
NLGSLLAGEEIFYTTGSRLNGDTGRNIFGYVTGGYTFNETV
RVGADFVYGGTKTEAANHLGGGKKLEAVARVDYKYSPKL
NFSAFYSYVNLDQGVNTNESADHSTVRLQLYKF.
The model was constructed based on the similar second-
ary structures exhibited by porins [30]. The core structure of
MOMP was initiated by using the skeleton of the anion-
selective porins from Co. acidovorans (1E54.pdb) and P. aerugi-
nosa (2QTK.pdb) [55] as templates to build the beta-barrels.
A combination of HYPERCHEM (HYPERCHEM PROFESSIONAL
7.51), CHIMERA (UCSF) [56] and the LEaP module as
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the loops and turns. The initial structure was heated from 0
to 325 K with a restraint of 10 kcal mol21 A˚22 on residues
of beta-barrels to avoid the effect of conformational changes
in loops on beta-barrels for a period of 200 ps in four steps,
followed by simulations from 0 to 325 K for another period
of 200 ps without any restraints in four steps. The system
was further simulated at 300 K for a period of 8 ns. The
ff99SB force field [57] was employed and solvation effects
were incorporated using the Generalized Born model [58],
as implemented [59] in AMBER. A lower energy structure
was chosen and this was glycosylated at the residue 268
with Gal(b1–3)-GalNAc(b1–4)-GalNAc(b1–4)-GalNAc-a-
linked to the protein using xleap as implemented in AMBER.
The Glycam04 force field [60–62] was used to model the
carbohydrate unit. The charge on the oxygen of the side
chain of Thr was changed from 20.6761 to 20.4599 and the
atom type of OS was assigned. The angle and dihedral
parameters for dimethylether (CT-OS-CG) and dimethoxy-
methane (H2-CG-OS-CT) were used for the glycosylated
angle and dihedral for the carbohydrate linkage. The
system was minimized with 500 steps of the steepest descent
minimization followed by 500 steps of conjugate gradient
minimization and heated at 400 K for a period of 10 ps to
avoid bad contacts with a restraint of 10 kcal mol21 A˚22 on
the protein backbone. The system was heated from 0 to
325 K for a period of 200 ps without any restraints, followed
by a simulation at 300 K for a period of 3.5 ns. Root-mean-
square deviation (RMSD) analysis for the complex system
was carried out on the trajectories by the ptraj module of
AMBER (v. 10). Three-dimensional structures were displayed
using CHIMERA (UCSF) [63], and RMSD graphics were gener-
ated by XMGRACE. Docking calculations were performed to
accommodate the Lewis antigen (Leb) and H-II antigen
within the cavity of the protein. Docking of the Leb was car-
ried out using DOCK v. 6.0 [64]. Docking was performed with
default settings to obtain a population of possible confor-
mations and orientations for Leb at the binding site.
Spheres around the centre of the binding pocket were defined
as the binding pocket for the docking runs. DOCK v. 6.0
employs sphgen to produce spheres and because sphgen
cannot handle more than 99 999 spheres, the residues form-
ing loops were stripped off, and thus the calculations of
spheres and grids were only performed with the beta-barrel
forming the cavity. Then, the coordinates of the Leb obtained
were recorded and AM1-Bcc (Austian model with Bond and
charge correction) [65] atomic partial charges and atom types
of general amber force field [66] were assigned for them using
antechamber as implemented in AMBER. Xleap was used to
accommodate the Leb within the cavity of MOMP with com-
bine command as well as to produce topology/parameter
and coordinate files. The atom type of Leb was changed to
those described in the Glycam04 force field [60–62]. The
system was minimized, followed by MD simulation at
300 K for about 6.0 ns. The same procedure was applied to
the glycosylated protein.
5.10. Auto-agglutination assay
Campylobacter jejuni strains were grown overnight in broth
under microaerophilic conditions at 378C, with shaking. Cul-
tures were filtered to remove large aggregates (5 mm pore size
filters; Millipore) and adjusted to OD600 of 1.0. One millilitreof culture was transferred to a cuvette, left at room temperature
and OD600 monitored every 10–20 min for up to 6 h.
5.11. Biofilm assay
The method carried out was adapted from [67,68]. Campylo-
bacter jejuni strains were grown overnight in MH broth
under microaerophilic conditions at 378C, with shaking.
The OD600 of those cultures was measured and used to inocu-
late MH broth (for inhibition studies containing 10 mg ml21
of BgAgs) to get a final OD600 of 0.02. One hundred and
fifty microlitres of broth was added to wells of polystyrene
96-well plates (Nunc) with control wells containing broth
alone. The plates were incubated under the same microaero-
philic conditions at 378C with shaking for 2 days. Following
incubation, biofilm formation was quantified. Briefly, liquid
medium was removed, and the plate washed three times
with PBS-T. Then, 150 ml of 1% crystal violet was added
into each well, and the plate covered and stained for 5 min.
The crystal violet was removed, and the dye on the plate
was resolved by adding 200 ml of 33% glacial acetic acid.
Plates were then measured using an ELISA reader at 595 nm.
5.12. Caco-2 association assays
Association assays were essentially carried out as previously
described [10]. Briefly, 24-well tissue culture plates were
seeded with Caco-2 cells in DMEMþ 5% fetal calf serum þ
antibiotic/antimycotic solution (Invitrogen) and incubated
until fully confluent and then for an additional 3–4 days until
cells were showing evidence of differentiation (formation of
domes and visible thickening of the monolayer). One day
prior to infection, the culture medium was changed to
DMEMþ 2% serum (no antibiotics). For inhibition
experiments, 20 mg ml21 purified NCTC11168 MOMP or
MOMPT268T/G, in DMEM þ 2% serum, was added to mono-
layers for 3 h at 378C under an atmosphere of 5% CO2. After
washing unbound protein three times with PBS, 108 cfu per
well C. jejuni NCTC11168 or 11168MOMPT268T/G were added
andmonolayers incubated for 3 h at 378C under an atmosphere
of 5% CO2. Total association was assayed by washing three
times in PBS, followed by homogenization of monolayers in
0.5% sodium deoxycholate in PBS. Associated C. jejuni cells
were enumerated by serial dilution, and plating of aliquots
onto modified CCDA agar (Oxoid). Assays were repeated
three times in duplicate and statistically significant differences
assessed using Student’s t-test.
5.13. Chicken colonization study
Briefly, 20 six-weeks-old White Leghorn chickens derived
from specific pathogen-free (SPF) parents (Lohmann’s,
Germany) were randomly divided into two groups (n ¼ 10
per group) and housed in separate isolators with unlimited
food and water. At day one, all birds in both groups were
challenged by oral gavage with 3  103 cfu C. jejuni resus-
pended in 100 ml PBS. Necropsies were performed on all
birds at 7 days post-challenge. Caeca and liver were removed
aseptically to quantify colonization levels of bacteria by plat-
ing out serial dilutions of gut contents and homogenized
liver onto blood agar plates containing Skirrow’s antibiotics
and cefoperazone (20 mg ml21) [69]. The detection limit for
colonization was 102 cfu g21 caecal content.
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